



Institut für Tropenmedizin Wilhelmstr. 27 72074 Tübingen

Dr Henning Gädeke
Chair of the Global Health EDCTP3 Joint Undertaking Governing
Board
c/o Dr Michael Makanga
Global Health EDCTP3 Joint Undertaking Executive Director
Global Health EDCTP3 Joint Undertaking
56 – 60 Avenue de la Toison d'Or
1060 Brussels
Belgium

Medizinische Klinik, Abteilung VII
Institut für Tropenmedizin,
Reisemedizin und Humanparasitologie

Kompetenzzentrum Baden-Württemberg

Professor Dr. Peter G. Kremsner
Direktor
Dr. med. Dr. rer. nat. Carsten Köhler
Direktor Kompetenzzentrum

Wilhelmstr. 27 D-72074 Tübingen

Telefon (07071) 29-8 2365
Fax (07071) 29- 5267

26 September 2025

Letter of endorsement

Dear Dr Gädeke

On behalf of the Eberhard Karls Universität Tübingen (UT), established in Geschwister Scholl Platz, 72074 Tübingen, Germany, VAT No. DE812383453 and in accordance with Council Regulation (EU) No 2085/2021 of 19th November 2021 establishing the joint undertakings under Horizon Europe and specifically Article 9 therein, we hereby submit an application to become contributing partners to the Global Health EDCTP3 Joint Undertaking (Global Health EDCTP3 JU).

The Institute of Tropical Medicine at the UT focusses on research, education, and patient care in tropical medicine, human parasitology and travel medicine. Our main research focus lies on malaria and helminth infections, as well as on the conduct of Phase I to IV drug and vaccine clinical studies. Our work has been instrumental in advancing new therapeutic strategies for malaria. Over the past three decades, we had contributed to the development of every new antimalarial drug and combination, setting benchmark standards for clinical research in the field. The clinical trials we designed and led with combinations such as atovaquone–proguanil, amodiaquine–artesunate, and pyronaridine–artesunate were pivotal to their successful approval and subsequent adoption in clinical practice. Altogether, our work is contributing to the advancement of new drugs and/or combinations for treatment and prevention of malaria in sub-Saharan Africa and globally, a common objective with Global Health EDCTP3 JU.

In the absence of feedback from Global Health EDCTP3 before the given deadline, this document serves as a provisional letter of endorsement.

Universitätsklinikum Tübingen
Anstalt des öffentlichen Rechts, Sitz Tübingen
Steuer-Nr. 86156/09402
USt.-ID: DE 146 889 674
Geissweg 3
72076 Tübingen
Tel. +49 7071 29-0
www.medizin.uni-tuebingen.de

Aufsichtsrat
Dr. Hans J. Reiter (Vorsitzender)
Vorstand
Prof. Dr. Jens Maschmann (Vorsitzender)
Dr. Daniela Harsch (Stellv. Vorsitzende)
Prof. Dr. Ulrike Ernemann
Prof. Dr. Bernd Pichler
Klaus Tischler

Banken
Baden-Württembergische Bank Stuttgart:
(BLZ 600 501 01) Konto-Nr. 7477 5037 93
IBAN: DE 41 6005 0101 7477 5037 93
BIC (SWIFT-Code): SOLADEST600
Kreissparkasse Tübingen:
(BLZ 641 500 20) Konto-Nr. 14 144
IBAN: DE 79 6415 0020 0000 0141 44
BIC (SWIFT-Code): SOLADES1TUB

UT commits to contribute in-kind (IKOPS) throughout the duration of the FACT project (i.e. 60 months). This support includes personnel costs, travel costs and purchase of consumables. This contribution strengthens the ability of the JU to deliver on its objectives by ensuring seamless scientific leadership, reliable laboratory analyses and diligent data management for the FACT project.

We estimate the total value of this in-kind contribution to be EUR 462,156.00 for the 60-month duration of the FACT project:

- Personnel costs: EUR 439,266 (additional time for project manager, clinical trial specialist, post doc and technician)
- Travel costs: EUR 12,000 (additional clinical trial oversights)
- Other goods, works and services: EUR 10,890 (additional consumables and working appliances).

We confirm the following:

1. We will comply with the Horizon Europe Regulation (EU) No 2021/695; Council Regulation (EU) No 2085/2021 establishing the joint undertakings under Horizon Europe; the Model Grant Agreement for Horizon Europe and applicable Global Health EDCTP3 JU rules, including the relevant work programmes and in particular the call conditions therein.
2. We will keep all information received in the context of our involvement as contributing partner to the Global Health EDCTP3 JU confidential. This confidentiality obligation applies in particular but is not limited to the areas of Global Health EDCTP3 JU call topic preparation and publication, proposal submission and evaluation, and consortium formation. We further understand that this obligation strictly prohibits the release of confidential information to any legal entities save where specifically authorised by Global Health EDCTP3 JU. Internal dissemination of information within our organisation will be done on the basis of the "need-to-know" principle.
3. We are confident of our ability to fulfil the above commitments and further confirm our understanding that the Global Health EDCTP3 JU will allocate resources to the above topic based on these commitments.
4. The value of our contribution will be based on costs calculated in accordance with Article 6 of the Horizon Europe Model Grant Agreement.
5. We accept that additional modalities regarding the provision of our contribution may be defined in subsequent agreements or documents, such as a funding agreement and topic text.

Yours faithfully



Peter G. Kremsner,
Medical Director, Institute of Tropical Medicine Tübingen